贝伐珠单抗和伊立替康治疗的复发性III级胶质瘤患者生物标志物
62例复发性III级胶质瘤患者的临床和副临床数据，用于分析贝伐珠单抗和伊立替康治疗的预后生物标志物。
基本信息
资源简介
贝伐珠单抗和伊立替康治疗的复发性III级胶质瘤患者生物标志物
【数据集背景】
本数据集源站标题为《Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan》。配套论文《Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan》发表于 Cancer Investigation（2018），DOI：10.1080/07357907.2018.1430818。项目资助方：The Sejer Persson & Lis Klüver Persson Foundation and The Danish Cancer Society (R101-A6634-14-S7)。源站首次发布：2018-02-02。
【数据内容】
源站原始描述：Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predicti…
【数据结构与技术规格】
文件数 2 个，合计 562.88 KB。icnv_a_1430818_sm9825.pdf：application/pdf，309.89 KB。icnv_a_1430818_sm9824.pdf：application/pdf，252.99 KB。数据集 DOI：10.6084/m9.figshare.5850042.v1。
【主题与分类】
源站学科分类：Medicine、Cell Biology、Genetics、Pharmacology、Biotechnology、Environmental Sciences not elsewhere classified。主题标签：Cancer biomarkers、Glioma、Bevacizumab、Recurrent、Prognosis and response predictions。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Biomarkers_in_Recurrent_Grade_III_Glioma_Patients_Treated_with_Bevacizumab_and_Irinotecan/5850042
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Taylor & Francis. Toft, Anders; Urup, Thomas; Jarle Christensen, Ib; Regner Michaelsen, Signe; Lukram, Babloo; Grunnet, Kirsten; et al
【使用注意】
· 源站最后修改于 2023-05-31，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan
- DOI：10.6084/m9.figshare.5850042.v1
- 发布日期：2018-02-02
- 文件数：2 个
- 文件总体积：562.88 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Biomarkers_in_Recurrent_Grade_III_Glioma_Patients_Treated_with_Bevacizumab_and_Irinotecan/5850042
命令行下载
curl -L -o "icnv_a_1430818_sm9825.pdf" "https://ndownloader.figshare.com/files/10378536"
curl -L -o "icnv_a_1430818_sm9824.pdf" "https://ndownloader.figshare.com/files/10378539"
文件清单
icnv_a_1430818_sm9825.pdf（309.89 KB）icnv_a_1430818_sm9824.pdf（252.99 KB）
文件总体积 562.88 KB（源站 API 实测）。
数据加载示例（图像类）
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.5850042.v1（source: https://tandf.figshare.com/articles/dataset/Biomarkers_in_Recurrent_Grade_III_Glioma_Patients_Treated_with_Bevacizumab_and_Irinotecan/5850042）。
需要用于商业化训练或医疗器械注册（NMPA/FDA）？
公开数据往往缺乏完整的病理回证与专家标注。千方医数集依托陕川双基地与超十家三甲医院直连，提供完全合规、去标识化、支持注册级质控的专病数据集交易服务。
